Scholar Rock gets FDA fast track for apitegromab FSHD Phase 2 FORGE
Scholar Rock received FDA Fast Track Designation for its apitegromab FSHD program as participant dosing started in Phase 2 of the FORGE trial.
Story updates
12:00:30 PM UTC
SquawkNews
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that the FDA has granted Fast Track and Orphan Drug de…
12:08:28 PM UTC
SquawkNews
SRRK - Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.